Loading patent…
AssigneesGeorg-August-Universität Göttingen Stiftung Öffentlichen Rechts, UniversitäT Regensburg
InventorsMarco Prinz, Wolfgang Bruck, Alexander Mildner, Matthias Mack
Estimating the term…
The invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament utilized for the treatment of multiple sclerosis and/or rheumatoid arthritis in a subject that is preferably a primate or a human. In another embodiment, the invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament that is utilized for depleting monocytes in subjects suffering from multiple sclerosis and/or rheumatoid arthritis. The invention further relates to corresponding in vitro methods and therapeutic methods. And antibody which binds to CD 14, for example, can be used in addition to the antibody that can bind to CCR2.
A medicament containing a monoclonal antibody which specifically binds to loop 1+first half of loop 2 of the extracellular human chemokine receptor CCR2 domain, wherein the monoclonal antibody is Doc-2.
A method for depleting monocytes comprising contacting the monocytes with a monoclonal antibody which specifically binds to loop 1+first half of loop 2 of the extracellular human chemokine receptor CCR2 domain, wherein the monoclonal antibody is Doc-2.
A method for depleting monocytes in a human subject comprising the step of administering to the subject an effective dose of a monoclonal antibody Doc-2 which specifically binds to loop 1+first half of loop 2 of extracellular human CCR2 domain.
A method for depleting monocytes in a human subject comprising the step of administering to the subject a monoclonal antibody which specifically binds to loop 1+first half of loop 2 of the extracellular human CCR2 domain, wherein the monoclonal antibody is Doc-2.
Dependencies are inferred from the claim text.